Can Heart-Focused care cut risks for prostate cancer patients?

NCT ID NCT07223385

Recruiting now Disease control Sponsor: Cedars-Sinai Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 07, 2026 · Updated 5 times

Summary

This study tests whether early referral to a cardio-oncology specialist can lower heart risks in prostate cancer patients receiving long-term hormone therapy (ARPI). About 80 men with high-risk or advanced prostate cancer and additional heart risk factors will be assigned to either a cardio-oncology consultation or standard care. The main goal is to see if more heart medications (like statins or blood pressure drugs) are started or adjusted within three months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cardio-oncology consultation (guidelines-based personalized management)
What this could lead to: If successful, this could show that early heart-focused care reduces cardiovascular risk in prostate cancer patients on long-term hormone therapy.
What could go wrong: This is a small Phase 2 trial (80 people) testing a care process, not a new drug. It may not prove that heart events are actually prevented.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CV RISK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder disease metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CV RISK PROSTATE CANCER (DIAGNOSIS) PROSTATE CANCER STAGE IV

Contacts and locations

Locations

Cedars Sinai Medical Center
RECRUITING

Los Angeles, California, 90048, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.